hbv
genotyp
includ
clinic
relev
nucleosid
analogresist
hbv
isol
conclus
first
exampl
small
molecul
select
inhibit
hbv
entri
decreas
ntcp
transport
activ
suggest
antihbv
activ
function
separ
bile
acid
transport
broadli
activ
antihbv
molecul
potenti
candid
develop
new
drug
fewer
advers
effect
lay
summari
studi
identifi
new
compound
select
inhibit
hepat
b
viru
hbv
entri
impair
bile
acid
uptak
evid
offer
new
strategi
develop
antihbv
drug
fewer
side
effect
background
aim
sodium
taurochol
cotransport
polypeptid
ntcp
main
target
hepat
b
viru
hbv
specif
entri
inhibitor
unfortun
agent
also
block
ntcp
transport
bile
acid
hepatocyt
thu
potenti
caus
advers
effect
aim
identifi
small
molecul
inhibit
hbv
entri
maintain
ntcp
transport
function
method
character
seri
cyclosporin
csa
deriv
antihbv
activ
ntcp
bind
specif
use
cell
overexpress
ntcp
primari
human
hepatocyt
four
potent
deriv
test
capac
prevent
hbv
entri
maintain
ntcp
transport
function
antivir
activ
differ
hbv
genotyp
analys
result
identifi
sever
csa
deriv
inhibit
hbv
infect
submicromolar
ic
among
show
low
activ
calcineurin
cn
cyclophilin
cyp
two
major
csa
cellular
target
suggest
instead
compound
interact
directli
ntcp
inhibit
viral
attach
host
cell
immunosuppress
function
importantli
found
impair
ntcpdepend
uptak
bile
acid
inhibit
multipl
hepat
b
viru
hbv
infect
worldwid
public
health
problem
estim
chronic
infect
approxim
million
individu
chronic
hbv
infect
elev
risk
develop
liver
cirrhosi
hepatocellular
carcinoma
current
clinic
treatment
hbv
infect
includ
interferon
ifn
nucleo
ide
analog
na
ifna
pegyl
form
pegifna
modul
host
immun
respons
viral
infect
directli
inhibit
hbv
replic
hepatocyt
na
includ
adefovir
entecavir
etv
lamivudin
telbivudin
tenofovir
suppress
hbv
replic
inhibit
revers
transcript
agent
significantli
improv
progress
hbvassoci
pathogenesi
howev
rare
lead
complet
elimin
hbv
infect
cell
treatment
studi
human
immunodefici
viru
hiv
hepat
c
viru
hcv
shown
multidrug
cocktail
greatli
improv
clinic
outcom
achiev
better
antihbv
treatment
futur
develop
new
antihbv
agent
target
differ
step
hbv
life
cycl
applic
multidrug
treatment
need
cyclosporin
csa
wellknown
immunosuppress
agent
classifi
calcineurin
cn
inhibitor
clinic
use
prevent
graft
reject
organ
transplant
csa
primarili
target
cellular
peptidyl
prolyl
ci
transisomeras
cyclophilin
cyp
suppress
enzymat
activ
result
csacyp
complex
subsequ
bind
cn
inhibit
phosphatas
activ
turn
inactiv
nfat
essenti
transcript
factor
immun
respons
addit
primari
activ
cypsand
cn
inhibit
csa
also
report
inhibit
transport
activ
membran
transport
famili
thu
far
csa
report
inhibit
replic
numer
virus
includ
hiv
hcv
hbv
herpesvirus
dengu
viru
west
nile
viru
human
papillomaviru
coronavirus
case
cypinhibit
princip
mechan
antivir
activ
cyp
play
critic
role
viral
life
cycl
group
recent
report
csa
inhibit
hbv
entri
target
membran
transport
sodium
taurochol
cotransport
polypeptid
ntcp
hbv
enter
hepatocyt
via
specif
interact
region
hbv
larg
surfac
protein
ntcp
recent
identifi
hbv
entri
receptor
ntcp
specif
express
hepat
basolater
membran
function
cotransport
bile
acid
sodium
ion
hepatocyt
identif
ntcp
hbv
receptor
rais
entri
process
attract
target
drug
develop
inhibit
entri
step
subsequ
format
coval
close
circular
dna
cccdna
persist
viral
reservoir
difficult
elimin
current
treatment
prevent
date
sever
compound
report
inhibit
hbv
infect
target
ntcp
includ
myrcludexb
irbesartan
ezetimib
ritonavir
vanitaracin
bile
acid
addit
csa
howev
drug
also
inhibit
transport
function
ntcp
impair
sodiumdepend
bile
acid
uptak
may
induc
signific
advers
effect
ntcpdefici
mice
patient
carri
defect
polymorph
mutat
ntcp
exhibit
elev
level
serum
bile
acid
develop
relat
patholog
includ
growth
retard
hypercholanemia
thu
signific
challeng
identifi
compound
specif
inhibit
hbv
infect
target
ntcp
without
effect
bile
acid
uptak
studi
describ
identif
new
csa
deriv
inhibit
hbv
infect
without
affect
transport
function
ntcp
moreov
antihbv
activ
achiev
compound
minim
inhibit
activ
cyp
cn
importantli
compound
effect
entri
multipl
hbv
genotyp
clinic
relev
naresist
hbv
isol
nonimmunosuppress
csa
deriv
alisporivir
develop
antihcv
candid
clinic
trial
phase
ii
iii
find
suggest
csa
deriv
constitut
use
platform
discoveri
novel
antihbv
agent
specif
activ
less
advers
effect
cell
primari
human
hepatocyt
phoenixbio
cultur
describ
previous
parent
cell
purchas
atcc
cell
confirm
mycoplasmaneg
hbv
genotyp
use
studi
mainli
deriv
cultur
supernat
cell
describ
previous
hbv
genotyp
c
carri
mutat
prepar
cultur
supernat
cell
transfect
correspond
express
plasmid
inocul
contain
virion
nucleocapsid
without
envelop
ratio
hbv
supplementari
fig
hbv
infect
perform
fig
fig
fig
genom
equival
geq
cell
hbv
geq
contain
hbv
dna
virion
nucleocapsid
presenc
describ
previous
bile
acid
uptak
activ
measur
presenc
absenc
sodium
use
cell
primari
human
hepatocyt
essenti
describ
cell
preincub
compound
min
incub
h
taurochol
acid
tca
presenc
compound
min
allow
substrat
uptak
cell
radioact
insid
cell
measur
liquid
scintil
statist
signific
determin
use
student
test
p
p
detail
materi
method
describ
supplementari
materi
investig
antihbv
activ
synthes
csa
deriv
design
sci
seri
cell
overexpress
human
ntcp
gene
cell
suscept
hbv
infect
expos
hbv
presenc
absenc
compound
h
wash
free
hbv
inoculum
compound
cell
cultur
addit
day
absenc
compound
hbv
protein
detect
indic
hbv
infect
hepat
b
surfac
hb
antigen
secret
cultur
supernat
fig
hepat
b
core
hbc
protein
cell
fig
day
post
infect
greatli
reduc
peptid
nmyristoyl
peptid
consist
aa
region
hbv
larg
surfac
protein
posit
control
among
csa
deriv
show
signific
reduct
hb
hbc
without
caus
cytotox
fig
contrast
csa
deriv
includ
show
signific
effect
hbv
infect
fig
csa
known
primarili
bind
cellular
cyclophilin
cyp
addit
interact
phosphatas
calcineurin
cn
essenti
immunosuppress
function
character
activ
new
csa
deriv
evalu
effect
deriv
inhibitori
activ
cn
cypa
shown
tabl
compound
includ
lost
abil
cn
inhibit
indic
elimin
immunosuppress
activ
tabl
deriv
show
weak
bind
cypa
tabl
drug
caus
immunosuppress
may
promot
viru
infectionrepl
patient
desir
immunosuppress
elimin
new
agent
base
result
focus
four
csa
deriv
follow
studi
includ
show
high
antihbv
activ
immunosuppress
abil
precis
evalu
antihbv
activ
new
csa
deriv
hbv
infect
assay
perform
primari
cultur
human
hepatocyt
physiolog
relev
model
csa
deriv
fig
significantli
decreas
hbv
infect
cell
monitor
hbv
dna
cccdna
cell
day
post
infect
fig
c
hepat
hbe
antigen
secret
cultur
supernat
consist
reduc
treatment
compound
dosedepend
manner
fig
halfmaxim
inhibitori
concentr
ic
calcul
lm
order
potent
csa
fig
compound
show
signific
cytotox
effect
primari
human
hepatocyt
lm
halfmaxim
cytotox
concentr
cc
supplementari
fig
hbv
life
cycl
compos
multipl
step
includ
earli
phase
attachmententri
traffick
nucleu
cccdna
format
replic
phase
transcript
nucleocapsid
assembl
revers
transcript
envelop
releas
identifi
step
csa
deriv
activ
within
hbv
life
cycl
assess
effect
four
csa
deriv
hbv
entri
replic
process
hbv
replic
evalu
use
cell
summari
antihbv
activ
also
shown
neg
low
medium
high
repres
strength
activ
hbc
area
permiss
hbv
replic
entri
step
treat
cultur
compound
six
day
fig
hbv
dna
releas
cultur
supernat
significantli
reduc
nucleosid
analog
entecavir
posit
control
csa
deriv
fig
contrast
csa
deriv
inhibit
earli
phase
infect
shown
fig
c
report
csa
inhibit
hbv
entri
prevent
attach
ntcp
therefor
perform
bind
assay
evalu
effect
csa
deriv
attach
host
cell
assay
fluorescentlabel
peptid
attach
onto
host
cell
reduc
treatment
csa
deriv
inact
csa
deriv
hbv
infect
fig
quantifi
data
c
pictur
result
indic
csa
deriv
inhibit
hbv
attach
onto
host
cell
report
csa
interact
ntcp
cell
surfac
host
hepatocyt
thu
investig
whether
csa
deriv
could
bind
ntcp
use
surfac
plasmon
reson
spr
analysi
control
experi
confirm
recombin
ntcp
protein
use
studi
supplementari
fig
materi
method
could
specif
interact
aa
peptid
spr
analysi
supplementari
fig
pull
assay
supplementari
fig
competit
inhibit
bind
host
cell
supplementari
fig
show
recombin
ntcp
protein
least
part
function
shown
fig
csa
deriv
shown
bind
recombin
ntcp
protein
dosedepend
manner
fig
left
signific
interact
observ
use
bovin
serum
albumin
bsa
neg
control
fig
right
thu
csa
deriv
interact
ntcp
similar
csa
date
sever
antihbv
entri
inhibitor
interact
ntcp
report
includ
myrcludexb
ezetimib
irbesartan
ritonavir
vanitaracin
bile
acid
addit
csa
possibl
induc
signific
advers
effect
impair
ntcp
transport
activ
ntcpdefici
mice
human
carri
ntcp
mutat
impair
transport
function
develop
elev
bile
acid
level
serum
relat
patholog
investig
whether
four
csa
deriv
inhibit
sodiumdepend
bile
acid
uptak
ntcp
transport
activ
evalu
cell
fig
primari
human
hepatocyt
fig
presenc
absenc
excess
amount
csa
deriv
lm
use
h
label
taurochol
acid
tca
substrat
shown
fig
peptid
csa
decreas
sodiumdepend
tca
uptak
indic
ntcp
transport
inhibitori
activ
cell
report
previous
fig
dark
blue
bar
among
csa
deriv
show
appar
reduct
tca
uptak
significantli
affect
ntcp
activ
fig
dark
blue
bar
primari
human
hepatocyt
addit
within
sci
seri
significantli
reduc
bile
acid
uptak
fig
doserespons
curv
inhibit
ntcp
transport
activ
indic
dramat
impair
bile
acid
uptak
case
csa
show
signific
effect
transport
fig
supplementari
fig
although
still
possibl
inhibit
ntcp
transport
higher
concentr
clearli
shown
activ
ntcp
transport
much
lower
csa
ic
lm
csa
respect
result
reveal
two
type
antihbv
entri
inhibitor
impair
bile
acid
uptak
minim
affect
transport
function
effect
like
due
enhanc
ntcp
endocytosi
csa
deriv
appar
chang
cell
surfac
local
ntcp
supplementari
fig
data
suggest
certain
compound
inhibit
hbv
entri
without
significantli
affect
transport
function
ntcp
far
suggest
molecular
determin
ntcp
critic
hbv
entri
overlap
requir
bile
acid
transport
confirm
whether
function
bile
acid
transport
capac
support
hbv
entri
distinguish
search
compound
bind
ntcp
inhibit
function
bile
acid
transport
inhibit
hbv
infect
sulfobromophthalein
known
function
substrat
ntcp
interact
bile
acid
pocket
ntcp
shown
fig
supplementari
fig
sulfobro
mophthalein
impair
bile
acid
uptak
sodiumcontain
sodiumfre
condit
cell
affect
bile
acid
uptak
ntcpdefici
cell
suggest
sulfobromophthalein
inhibit
ntcpmediat
bile
acid
transport
report
previous
fig
supplementari
fig
howev
compound
inhibit
hbv
infect
concentr
condit
fig
furthermor
deplet
sodium
inactiv
bile
acid
transport
mediat
ntcp
fig
activ
support
hbv
infect
still
present
fig
report
previous
data
demonstr
two
function
ntcp
transport
bile
acid
support
hbv
infect
separ
favor
concept
develop
hbv
entri
inhibitor
without
affect
bile
acid
transport
examin
effect
csa
deriv
hepat
viru
hdv
enter
host
hepatocyt
ntcp
shown
fig
hdv
infect
cell
significantli
reduc
presenc
csa
deriv
fig
consist
essenti
role
ntcp
hdv
entri
assess
antivir
potenti
csa
deriv
investig
antihbv
activ
differ
genotyp
hbv
entecavirresist
hbv
primari
human
hepatocyt
experi
shown
fig
use
genotyp
isol
addit
effect
hbv
genotyp
show
new
csa
deriv
inhibit
infect
hbv
genotyp
b
c
fig
importantli
compound
also
inhibit
infect
clinic
relev
entecavirresist
hbv
carri
mutat
fig
thu
csa
deriv
demonstr
consider
potenti
develop
pangenotyp
antihbv
agent
find
ntcp
function
hbv
entri
receptor
enabl
discoveri
effort
identifi
agent
specif
inhibit
hbv
entri
date
myrcludexb
csa
irbesartan
ezetimib
ritonavir
vanitaracin
report
inhibit
hbv
infect
directli
target
ntcp
howev
agent
potenti
inhibit
function
ntcp
uptak
bile
acid
hepatocyt
although
ic
myrcludexb
inhibit
ntcp
transport
less
hbv
entri
inhibit
thu
possibl
seek
window
inhibit
hbv
infect
without
signific
loss
transport
function
small
molecul
shown
similar
ic
inhibit
transport
hbv
inhibit
therefor
seek
small
molecul
inhibit
hbv
infect
without
affect
ntcp
transport
activ
one
major
challeng
exploit
entri
inhibit
safe
effect
therapi
hbv
previous
point
mutat
analys
within
ntcp
gene
suggest
close
relationship
transport
activ
viral
receptor
function
substitut
amino
acid
residu
relat
transport
function
includ
sodium
bind
bile
acid
bind
found
reduc
complet
abolish
capac
ntcp
bind
support
hbv
entri
result
suggest
residu
essenti
transport
function
also
util
hbv
entri
host
cell
addit
previous
report
inhibitor
ntcp
transport
activ
found
reduc
capac
ntcp
support
hbv
infect
report
clearli
demonstr
two
function
ntcp
distinguish
possibl
mode
mechan
cyclosporinsntcp
interact
discuss
supplementari
note
supplementari
materi
present
studi
identifi
csa
deriv
inhibit
hbv
entri
without
affect
ntcp
transport
activ
equival
even
higher
antientri
activ
parent
csa
thu
minim
sideeffect
ntcp
function
bile
acid
transport
possibl
develop
compound
accept
sideeffect
profil
strong
support
concept
separ
antivir
activ
compound
inhibitori
effect
origin
function
receptor
found
among
antivir
drug
hiv
maraviroc
target
hiv
coreceptor
inhibit
hiv
entri
compar
potenc
maraviroc
also
inhibit
bind
cognat
ligand
rant
affect
bind
csa
also
report
potenti
weak
inhibit
activ
apic
sodiumdepend
bile
acid
transport
asbt
also
known
anoth
famili
transport
work
bile
acid
uptak
con
sistent
well
csa
show
signific
reduct
abst
transport
lm
supplementari
fig
exclud
possibl
two
deriv
potent
asbt
inhibitor
csa
immunosuppress
induc
compound
like
facilit
viral
infectionrepl
vivo
desir
immunosuppress
activ
csa
remov
achiev
develop
alisporivir
nonimmunosuppress
cyclophilin
inhibitor
antihcv
drug
csa
deriv
examin
present
studi
defici
calcineurin
inhibit
essenti
immunosuppress
activ
still
exert
antihbv
activ
interestingli
compound
also
found
weak
inhibit
cyclophilin
includ
modif
may
prefer
aspect
improv
specif
compound
activ
importantli
compound
effect
differ
hbv
genotyp
clinic
relev
entecavirresist
hbv
isol
moreov
agent
expect
rais
less
frequent
drug
resist
viral
speci
target
cellular
factor
thu
studi
show
advantag
csa
deriv
develop
new
antivir
agent
potent
welltoler
broadli
activ
inhibitor
hbv
hdv
infect
depth
deriv
analys
includ
antivir
activ
toxic
pharmacokinet
dynam
properti
vivo
expect
studi
partli
support
grantsinaid
ministri
health
labor
welfar
japan
ministri
educ
cultur
sport
scienc
technolog
japan
